Literature DB >> 7930725

Reduced virulence of rifampicin-resistant mutants of Francisella tularensis.

N Bhatnagar1, E Getachew, S Straley, J Williams, M Meltzer, A Fortier.   

Abstract

Rifampicin-resistant mutants of a live vaccine strain (LVS) of Francisella tularensis were produced and screened for virulence in mice; 4 avirulent clones with intraperitoneal (ip) LD50s > 10(6) cfu, compared with 10(2) cfu for LVS, were characterized. Growth characteristics at 37 degrees C, surface envelope proteins, and lipopolysaccharide profiles of resistant mutants were identical to those of LVS. Polymerase activity of the mutants was more resistant than the enzyme from LVS to the inhibitory action of rifampicin. Growth rates for mutants and LVS were similar during the first 5 h at 42 degrees C, but viability of the mutants decreased to < 0.01% at 24 h. LVS and mutants differed in their ability to grow in vitro in host macrophages: LVS increased 580-fold over 72 h; mutants increased 33-fold. After ip inoculation of the organisms into mice, increasing numbers of LVS from peritoneal cells were isolated; mutants decreased over 4 days.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7930725     DOI: 10.1093/infdis/170.4.841

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Francisella tularensis induces cytopathogenicity and apoptosis in murine macrophages via a mechanism that requires intracellular bacterial multiplication.

Authors:  X H Lai; I Golovliov; A Sjöstedt
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

2.  Isolation of rifampin-resistant mutants of Listeria monocytogenes and their characterization by rpoB gene sequencing, temperature sensitivity for growth, and interaction with an epithelial cell line.

Authors:  R Morse; K O'Hanlon; M Virji; M D Collins
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

3.  Bactericidal activities of antibiotics against intracellular Francisella tularensis.

Authors:  M Maurin; N F Mersali; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

4.  Heat stress alters the virulence of a rifampin-resistant mutant of Francisella tularensis LVS.

Authors:  N B Bhatnagar; K L Elkins; A H Fortier
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

5.  Identification of differentially regulated francisella tularensis genes by use of a newly developed Tn5-based transposon delivery system.

Authors:  Blake W Buchan; Molly K McLendon; Bradley D Jones
Journal:  Appl Environ Microbiol       Date:  2008-03-14       Impact factor: 4.792

6.  Enhancement of vaccine efficacy by expression of a TLR5 ligand in the defined live attenuated Francisella tularensis subsp. novicida strain U112ΔiglB::fljB.

Authors:  Aimee L Cunningham; Kim Minh Dang; Jieh-Juen Yu; M Neal Guentzel; Hans W Heidner; Karl E Klose; Bernard P Arulanandam
Journal:  Vaccine       Date:  2014-07-19       Impact factor: 3.641

7.  Survival and growth of Francisella tularensis in Acanthamoeba castellanii.

Authors:  Hadi Abd; Thorsten Johansson; Igor Golovliov; Gunnar Sandström; Mats Forsman
Journal:  Appl Environ Microbiol       Date:  2003-01       Impact factor: 4.792

8.  In vivo Himar1-based transposon mutagenesis of Francisella tularensis.

Authors:  Tamara M Maier; Roger Pechous; Monika Casey; Thomas C Zahrt; D W Frank
Journal:  Appl Environ Microbiol       Date:  2006-03       Impact factor: 4.792

9.  Targeted inactivation of francisella tularensis genes by group II introns.

Authors:  Stephen A Rodriguez; Jieh-Juen Yu; Greg Davis; Bernard P Arulanandam; Karl E Klose
Journal:  Appl Environ Microbiol       Date:  2008-02-29       Impact factor: 4.792

10.  TPR1, a novel rifampicin derivative, demonstrates efficacy alone and in combination with doxycycline against the NIAID Category A priority pathogen Francisella tularensis.

Authors:  Jason E Cummings; Keaton W Slayden; Richard A Slayden
Journal:  JAC Antimicrob Resist       Date:  2021-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.